- China offers $325 bn in fiscal stimulus for ailing economy
- Small Quebec company dominates one part of NHL hockey: jerseys
- Boeing to cut 10% of workforce as it sees big Q3 loss
- Want to film in Paris? No sexism allowed
- US, European markets rise as investors weigh rates, earnings
- In Colombia, children trade plastic waste for school supplies
- JPMorgan Chase profits top estimates, bank sees 'resilient' US economy
- Little progress at key meet ahead of COP29 climate summit
- 'Party atmosphere': Skygazers treated to another aurora show
- Kyrgyzstan opens rare probe into glacier destruction
- European Mediterranean states discuss Middle East, migration
- Thunberg leads pro-Palestinian, climate protest in Milan
- Stock markets diverge before China weekend briefing
- EU questions shopping app Temu over illegal products risk
- Han Kang's books sell out in South Korea after Nobel win
- Shanghai markets sink ahead of briefing on mixed day for Asia
- Investors, analysts eye bigger China stimulus at Saturday briefing
- Musk unveils robotaxi, pledges it 'before 2027'
- At least 11 dead in Florida but Hurricane Milton not as bad as feared
- Asian markets mixed after Wall St drop, Shanghai dips before briefing
- Automaker Stellantis says CEO will retire in 2026
- Musk's promised robotaxi unveil delayed
- On US coast, wind power foes embrace 'Save the Whales' argument
- At least 10 dead in Florida after Hurricane Milton spawns tornadoes
- Internet Archive reels from 'catastrophic' cyberattack, data breach
- Wall Street stocks retreat from records on US inflation data
- Israel strikes central Beirut, killing 22
- Solar storm could impact US hurricane recovery efforts: agency
- Delta eyes Election Day travel pullback as profits climb
- Florida battered by hurricane, floods but spared 'worst-case scenario'
- UK's William and Kate in first joint public engagement since cancer treatment
- Over 200 women in legal talks with Harrods over Fayed abuse claims
- A very stiff breeze: BBC says sorry for 20,000 kph wind forecast
- Musk finally unveiling his long-promised robotaxi
- London's Frieze art fair goes potty for ceramics
- US, Europe stocks fall on US inflation data
- US consumer inflation eases to 2.4% in September
- Hurricane Milton tornadoes kill four in Florida amid rescue efforts
- South Korea's Han Kang wins literature Nobel
- Ikea posts fall in annual sales after lowering prices
- Stock markets diverge, oil gains after China rebounds
- World can't 'waste time' trading climate change blame: COP29 hosts
- South Korean same-sex couples make push for marriage equality
- Mumbai declares day of mourning for Indian industrialist Ratan Tata
- 7-Eleven owner restructures to fight takeover
- Sri Lanka recovering faster than expected: World Bank
- Hong Kong, Shanghai rally as most markets track Wall St record
- Uniqlo owner reports record annual earnings
- Hong Kong, Shanghai rally as markets track Wall St record
- Indonesia biomass drive threatens key forests: report
US approves sale of anti-overdose drug Narcan without prescription
The US drug regulator announced Wednesday that Narcan, the treatment which reverses overdoses, can be distributed without prescription, a move that comes as the country battles an acute opioid addiction crisis.
The Federal Drug Administration (FDA) said that four milligram nasal spray doses of naloxone hydrochloride, the generic name for Narcan, can be sold over the counter almost anywhere, from pharmacies to supermarkets to gas stations.
The FDA said they moved to address to mounting toll from opioid use, especially the synthetic and relatively easily made fentanyl, which has in the past five years increasingly replaced heroin and prescription pain killers as the main drug used by people addicted to opioids.
In the 12 months to October 2022, the US recorded 101,750 overdose deaths, mostly from fentanyl, the FDA said in a statement.
"The agency has used its regulatory authority to facilitate greater access to naloxone by encouraging the development of and approving an over-the-counter naloxone product to address the dire public health need,” said FDA Commissioner Robert Califf.
Narcan, by far the most commonly used version of naloxone, can quickly reverse the effects of an overdose.
Narcan will "bring someone back from basically the dead," Johnny Bailey, who has recovered from an opioid addiction and who trains people to administer the drug, explained in early March in Washington.
Previously administered mainly by injection, Narcan, produced by Emergent BioSolutions, was approved in its nasal spray form as a prescription drug in 2015.
With the toll from overdoses mounting each year, the FDA accelerated its review of Narcan for over-the-counter sales early this year.
The FDA said other producers of naloxone spray can gain approval on a case-by-case basis.
"Naloxone is a critical tool in addressing opioid overdoses," said FDA drug evaluation chief Patrizia Cavazzoni.
L.K.Baumgartner--CPN